Neurostimulation for Parkinson's Disease with Early Motor Complications

W.M.M. Schuepbach et al. · PI Guenther Deuschl, Prof.

Primary endpoint

PDQ-39

Population

Parkinson Disease; n=251

doi:10.1056/NEJMoa1205158

Historical

Current

Future

3 noemes

Historical

1 noeme

Published findings from this trial. Vote whether the expert body still believes each noeme stands given current evidence.

The EARLYSTIM trial's stated primary conclusion — Early STN-DBS improves quality of life in Parkinson disease patients with early motor complications vs. medical therapy. — replicates in independent cohorts.

neurology

Current

1 noeme

Noemes tracking active replication, subgroup analysis, or long-term follow-up. Vote on the likelihood the original effect holds.

Recent follow-up analyses of EARLYSTIM are confirming the original effect size in real-world data.

neurology

Future

1 noeme

Open forecast horizons tied to this trial. Vote your probability that each resolves TRUE by the declared horizon.

By 2028, DBS referral in PD will routinely be considered within 5 years of motor-complication onset (vs. the historical ≥10-year pattern).

neurology

71%

Semantically related trials

Nearest trials by noeme-centroid cosine distance. Lower = closer.

NCT01804355

0.1868

· 3 claims

A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke

NCT01778335

0.1964

· 3 claims

Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke

NCT02142283

0.2001

· 3 claims

Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct

NCT04402632

0.2003

· 3 claims

A Study of the Embolization of the Middle Meningeal Artery With ONYX™ Liquid Embolic System In the Treatment of Subacute and Chronic Subdural HEmatoma (EMBOLISE)

NCT02586415

0.2006

· 3 claims

Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging

NCT04816591

0.2041

· 3 claims

Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA